WO2024259048A3 - Thiazolopyridin-7(4h)-one wrn inhibitors - Google Patents

Thiazolopyridin-7(4h)-one wrn inhibitors Download PDF

Info

Publication number
WO2024259048A3
WO2024259048A3 PCT/US2024/033732 US2024033732W WO2024259048A3 WO 2024259048 A3 WO2024259048 A3 WO 2024259048A3 US 2024033732 W US2024033732 W US 2024033732W WO 2024259048 A3 WO2024259048 A3 WO 2024259048A3
Authority
WO
WIPO (PCT)
Prior art keywords
thiazolopyridin
wrn
compounds
inhibitors
thiazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/033732
Other languages
French (fr)
Other versions
WO2024259048A2 (en
Inventor
Derun Li
Florian Bartels
Justin Caravella
Robert Lee Dow
Nathan E. GENUNG
Silvana Marcel LEIT DE MORADEI
Angela V. West
Nikolay SITNIKOV
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nimbus Wadjet Inc
Original Assignee
Nimbus Wadjet Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nimbus Wadjet Inc filed Critical Nimbus Wadjet Inc
Priority to CN202480044318.1A priority Critical patent/CN121419979A/en
Publication of WO2024259048A2 publication Critical patent/WO2024259048A2/en
Publication of WO2024259048A3 publication Critical patent/WO2024259048A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present disclosure is directed to thiazolopyridin-7(4h)-one based compounds, including compounds of Formula I i.e., the isomeric 4H-[1,3]thiazolo[4,5-b]pyridin-7-one or 4H-[1,3]thiazolo[5,4-b]pyridin-7-one compounds, and pharmaceutically acceptable salts thereof, and compositions thereof, as well as methods of treatment of cancers such as those involving WRN protein, particularly cancers characterized as microsatellite instability-high (MSl-H) or mismatch repair deficient (dMMR).
PCT/US2024/033732 2023-06-13 2024-06-13 Thiazolopyridin-7(4h)-one wrn inhibitors Pending WO2024259048A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202480044318.1A CN121419979A (en) 2023-06-13 2024-06-13 Thiazolidine-7(4H)-one WRN inhibitor

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202363507932P 2023-06-13 2023-06-13
US63/507,932 2023-06-13
US202363519756P 2023-08-15 2023-08-15
US63/519,756 2023-08-15
US202363613655P 2023-12-21 2023-12-21
US63/613,655 2023-12-21

Publications (2)

Publication Number Publication Date
WO2024259048A2 WO2024259048A2 (en) 2024-12-19
WO2024259048A3 true WO2024259048A3 (en) 2025-02-27

Family

ID=93852894

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033732 Pending WO2024259048A2 (en) 2023-06-13 2024-06-13 Thiazolopyridin-7(4h)-one wrn inhibitors

Country Status (2)

Country Link
CN (1) CN121419979A (en)
WO (1) WO2024259048A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202502345A (en) 2023-06-08 2025-01-16 美商林伯士瓦吉特公司 Wrn inhibitors
WO2025215527A2 (en) 2024-04-10 2025-10-16 Novartis Ag Pharmaceutical combinations and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140206679A1 (en) * 2011-06-09 2014-07-24 Shanghai Huilun Life Science & Technology Co., Ltd Heterocyclic pyridone compound, and intermediate, preparation method and use thereof
WO2018229683A1 (en) * 2017-06-15 2018-12-20 Novartis Ag 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
US20230046859A1 (en) * 2021-05-26 2023-02-16 Novartis Ag Bicyclic Compounds and their Uses
WO2024105610A1 (en) * 2022-11-18 2024-05-23 Novartis Ag Pharmaceutical combinations and uses thereof
WO2024120378A2 (en) * 2022-12-05 2024-06-13 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Triazole compounds, preparation methods and medicinal uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140206679A1 (en) * 2011-06-09 2014-07-24 Shanghai Huilun Life Science & Technology Co., Ltd Heterocyclic pyridone compound, and intermediate, preparation method and use thereof
WO2018229683A1 (en) * 2017-06-15 2018-12-20 Novartis Ag 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
US20230046859A1 (en) * 2021-05-26 2023-02-16 Novartis Ag Bicyclic Compounds and their Uses
WO2024105610A1 (en) * 2022-11-18 2024-05-23 Novartis Ag Pharmaceutical combinations and uses thereof
WO2024120378A2 (en) * 2022-12-05 2024-06-13 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Triazole compounds, preparation methods and medicinal uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBCHEM [online] 21 January 2019 (2019-01-21), "3-(2-Methoxypyridin-4-yl)-5,6,7,8-tetrahydro 11,2,4]triazolo[4,3-a]pyrimidine", Database accession no. 136034193 *

Also Published As

Publication number Publication date
WO2024259048A2 (en) 2024-12-19
CN121419979A (en) 2026-01-27

Similar Documents

Publication Publication Date Title
WO2024259048A3 (en) Thiazolopyridin-7(4h)-one wrn inhibitors
GEP20237581B (en) 6,7-dihydro-5h-pyrido[2,3-c]pyridazine derivatives and related compounds as bcl-xl protein inhibitors and pro-apoptotic agents for treating cancer
GEAP202415945A (en) Bicyclic heterocycles as fgfr inhibitors
NZ766835A (en) Pharmaceutical compounds
MX2025011899A (en) PYRIDO[4,3-<i>D</i>]PYRIMIDINE COMPOUNDS
GEAP202215630A (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
MY140748A (en) Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
RU2412171C2 (en) Novel piperazine compound and use thereof as hcv polymerase inhibitor
ZA202309566B (en) 3,4-dihydro-2,7-naphthyridine-1,6(2h,7h)-diones as mek inhibitors
ZA200308696B (en) Nitrogen-containing bicyclic heterocycles for use as antibacterials.
MY130736A (en) Imidazo(4,5-c) pyridin-4-one derivatives
MX2022014168A (en) Salt and crystal forms of 4-amino-5-(6-(4-methylpiperazin-1-yl)-1 h-benzo[d]imidazol-2-yl)thieno[2,3-b]pyridin-6(7h)-one.
MX2023005626A (en) Pyrazolo[1,5-a]pyrazine derivatives as btk inhibitors.
MX2021002051A (en) Imidazo[1,2-b]pyridazines as trk inhibitors.
WO2022058745A3 (en) Imidazo[1,2-a]pyridine compounds and their use in therapy
MX2025010149A (en) [1,3]thiazolo[4,5-d]-pyrimidin-7-ones as inhibitors of nox4
WO2013042035A4 (en) Heterocyclic compounds as inhibitors of fatty acid biosynthesis for bacterial infections
CL2021003536A1 (en) 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1h-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine crystalline hydrate 3 . application divisional application 2284-2020
WO2024254511A3 (en) Wrn inhibitors
NO20013384L (en) Imidazo [4,5-c] pyridine-4-one derivatives
JOP20250019A1 (en) A new salt of the imidazopyridine compound, its crystalline form, and method of preparation
MX2023007641A (en) 4-amino-3-(4-phenoxyphenyl)-1,3- dihydro-2h-imidazo[4,5-c]pyridin -2-one derivatives and salts thereof.
MX2025004569A (en) 3a,4,5,6-tetrahydro-1 h-pyrazolo[3,4-c]pyridin-7(7ah)-one derivatives as factor xiia inhibitors
EP4267581A4 (en) Substituted imidazo[1,5-b]pyridazine compounds as kinase inhibitors and use thereof
MX2024008840A (en) 1,3,4,7-tetrahydro-2h-pyrrolo [3',2':5,6] pyrido[2,3-b] [1,4] oxazepine bc1-2 inhibitors.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24824123

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2024824123

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024824123

Country of ref document: EP

Effective date: 20260113

ENP Entry into the national phase

Ref document number: 2024824123

Country of ref document: EP

Effective date: 20260113

ENP Entry into the national phase

Ref document number: 2024824123

Country of ref document: EP

Effective date: 20260113

ENP Entry into the national phase

Ref document number: 2024824123

Country of ref document: EP

Effective date: 20260113